These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 31869855)
21. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent. Van der Plas SE; Kelgtermans H; De Munck T; Martina SLX; Dropsit S; Quinton E; De Blieck A; Joannesse C; Tomaskovic L; Jans M; Christophe T; van der Aar E; Borgonovi M; Nelles L; Gees M; Stouten P; Van Der Schueren J; Mammoliti O; Conrath K; Andrews M J Med Chem; 2018 Feb; 61(4):1425-1435. PubMed ID: 29148763 [TBL] [Abstract][Full Text] [Related]
22. Tobramycin is a suppressor of premature termination codons. Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394 [TBL] [Abstract][Full Text] [Related]
23. Investigating REPAIRv2 as a Tool to Edit Melfi R; Cancemi P; Chiavetta R; Barra V; Lentini L; Di Leonardo A Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640650 [TBL] [Abstract][Full Text] [Related]
33. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation. McGarry ME N Engl J Med; 2020 Feb; 382(7):684. PubMed ID: 32053310 [No Abstract] [Full Text] [Related]
34. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
35. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease. Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192 [TBL] [Abstract][Full Text] [Related]
36. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
37. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]